ClinicalTrials.gg
RecruitingNCT07707635IBS-CDEDUpdated Nov 10, 2026

IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel Syndrome

An interventional study of Modified Crohn's Disease Exclusion Diet (CDED) and Low FODMAP Diet in Irritable Bowel Syndrome (IBS), sponsored by Ariel University. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Ariel University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 10, 2026Now RecruitingFirst site in Israel+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Irritable Bowel Syndrome with a site in Israel — 2 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · Israel.

Planned enrollment
5th of 10
150 · median 110
Started
2026
with 1 other
No phase
5 of 11
2 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Ariel University

Among the 11 studies in Irritable Bowel Syndrome with a site in Israel, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 11th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

2 of the 11 studies in Irritable Bowel Syndrome with a site in Israel are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Irritable Bowel Syndrome with a site in Israel, or all of them as a file.
02

Study summary

Background: Irritable Bowel Syndrome (IBS) affects approximately 4.1% of the global population and imposes a significant personal and healthcare burden. Recent evidence highlights the role of low-grade inflammation, impaired intestinal permeability and gut microbiota dysbiosis in the pathophysiology of non-constipated IBS (IBS with predominate diarrhea; IBS-D and mixed type IBS; IBS-M). Most patients report food-related symptom exacerbation, making dietary intervention a cornerstone of treatment. While the low-FODMAP diet (LFD) is widely used to reduce fermentable carbohydrates and alleviate symptoms, it may negatively affect microbial diversity and lacks anti-inflammatory effects. In contrast, the Crohn's Disease Exclusion Diet (CDED), developed for Crohn's disease, has demonstrated the ability to reduce intestinal inflammation, improve barrier function, and promote a favorable microbiota profile. These mechanisms may be relevant and beneficial in IBS, but have yet to be studied in this population.

Objectives: To compare the efficacy of a modified CDED to the LFD for the treatment of non-constipated IBS symptoms, Hypothesis: A modified CDED will be at least as effective as the LFD in alleviating non-constipation IBS symptoms, stool consistency, quality of life, and psychological distress, while demonstrating superior effects on markers of low-grade inflammation, gut microbiota composition, and intestinal permeability.

Methods: This is a single-center, open-label, randomized study to be conducted at the Gastroenterology Department of Sheba Medical Center. 136 adults diagnosed with Rome IV-defined IBS-D or IBS-M and an IBS Symptom Severity Score (IBS-SSS) ≥175 will be randomized 1:1 to receive either a modified CDED or the LFD for 6 weeks. Accounting for a 10% dropout rate, the total sample size will be 150.

Following a 14-day screening period, eligible participants will undergo data collection at baseline, week 3 and week 6. Visit 1 (screening) will be conducted on-site; visits 2-4 will be remote. Participants will complete daily symptom diaries [Bristol Stool Form Scale (BSFS) and GI Visual Analogue Scale (VAS)], and weekly IBS-SSS. Validated questionnaires assessing psychological distress, somatization, extraintestinal symptoms, and quality of life will be administered at each time point.

Stool samples will be collected at baseline, week 3, and week 6. Fecal calprotectin (FC) and α1-Antitrypsin (A1AT) will be analyzed as markers of intestinal inflammation and permeability. Microbiota analysis will be conducted using 16S rRNA gene sequencing, with evaluation of microbial diversity, taxonomic shifts, and associations with clinical and biological outcomes.

Significance: This is the first study to evaluate the modified CDED as a dietary intervention for the treatment of IBS. It may offer a novel, inflammation-targeted alternative treatment for IBS.

Read the detailed description

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by chronic gastrointestinal symptoms in the absence of structural disease. Increasing evidence suggests that, particularly in non-constipated IBS (IBS-D and IBS-M), impaired intestinal barrier function, gut microbiota dysbiosis, mucosal immune activation, and low-grade inflammation contribute to symptom generation. These findings have shifted the focus of research toward dietary strategies that target underlying biological mechanisms rather than symptom reduction alone.

The low FODMAP diet is currently the most extensively studied dietary intervention for IBS and is recommended by international guidelines. However, despite its effectiveness in reducing gastrointestinal symptoms, concerns remain regarding its potential adverse effects on gut microbial diversity and the lack of evidence for improvement in intestinal inflammation or barrier integrity.

The Crohn's Disease Exclusion Diet (CDED) was originally developed for patients with Crohn's disease and has demonstrated favorable effects on intestinal inflammation, epithelial barrier function, and gut microbiota composition. Because several of these biological pathways are also implicated in IBS pathophysiology, an adapted version of the CDED may provide clinical benefits while simultaneously targeting disease mechanisms that are not addressed by current dietary approaches.

This study will evaluate, for the first time, an IBS-oriented adaptation of the CDED that excludes the enteral formula component used in Crohn's disease. In addition to evaluating clinical efficacy, the study will investigate potential biological mechanisms through serial assessment of fecal inflammatory markers, intestinal permeability markers, and gut microbiota composition. By integrating clinical, psychological, and biological outcomes, the study aims to determine whether this dietary intervention represents a mechanism-based alternative to the current dietary standard of care for patients with non-constipated IBS.

03

Conditions studied

  • Irritable Bowel Syndrome (IBS)

Keywords

  • Crohn's Disease Exclusion Diet (CDED)
  • Low FODMAP Diet
  • Diet Therapy
  • Gut Microbiota
  • Intestinal Permeability
  • Fecal Calprotectin
  • Alpha-1 Antitrypsin
  • IBS-D
  • IBS-M
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults, men, and women (≥18 years) are diagnosed with IBS-D or IBS-M according to Rome IV criteria.
  • Moderate-to-severe symptoms (IBS-SSS score ≥175).
  • Stable use of any IBS-related medications for ≥6 weeks before study enrollment, except for antibiotics

Exclusion criteria

Exclusion Criteria:

  • Coexisting GI diseases [e.g., Crohn's disease, ulcerative colitis, SIBO, celiac disease [positive transglutaminase (TTG) serology].
  • Disease that could explain or influence symptoms or GI function, including diabetes, thyroid disease [abnormal Thyroid-Stimulating Hormone (TSH)], and bariatric surgery.
  • Recent intestinal resection.
  • Pregnancy or breastfeeding.
  • Known food allergies.
  • Current active eating disorder
  • Participants already following a restrictive diet, including diets that overlap with the interventions in this study, will be excluded to prevent confounding effects on gut microbiota composition and gastrointestinal symptoms, and to ensure consistent baseline conditions. However, individuals who have discontinued such diets at least two to four weeks prior to enrollment may be eligible, allowing for a sufficient dietary to minimize residual effects on the gut microbiota.
  • Currently under obesity management medication treatment.
  • Vegans
  • Use of antibiotics within the 4 weeks prior to enrollment or during the study period.
  • Abnormal levels (for women\<11.5 gr/dl, for men\<13 gr/dl)29
  • Baseline CRP≥5
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Modified Crohn's Disease Exclusion Diet (CDED)

    Participants randomized to this arm will follow a modified Crohn's Disease Exclusion Diet (CDED) adapted for patients with irritable bowel syndrome. The intervention excludes the enteral formula used in the original CDED protocol and is delivered for 6 weeks with individualized dietary counseling.

    Other: Modified Crohn's Disease Exclusion Diet (CDED)

  • Active comparator
    Low FODMAP Diet

    Participants randomized to this arm will follow a standard low FODMAP diet for 6 weeks with individualized dietary counseling.

    Other: Low FODMAP Diet

Interventions

  • OtherModified Crohn's Disease Exclusion Diet (CDED)

    Participants will follow a modified Crohn's Disease Exclusion Diet (CDED) adapted for patients with irritable bowel syndrome. The intervention excludes the enteral formula used in the original CDED protocol and is delivered for 6 weeks with individualized dietary counseling.

  • OtherLow FODMAP Diet

    Participants will follow a standard low FODMAP diet for 6 weeks with individualized dietary counseling.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving a clinically meaningful response (≥50-point reduction in IBS Symptom Severity Score [IBS-SSS])

    The primary efficacy outcome is the proportion of participants achieving a clinically meaningful response, defined as a reduction of at least 50 points from baseline in the IBS Symptom Severity Score (IBS-SSS) after 6 weeks of treatment. The IBS-SSS is a validated questionnaire ranging from 0 to 500, with higher scores indicating greater symptom severity.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Proportion of participants achieving a ≥100-point reduction in IBS Symptom Severity Score (IBS-SSS)

    Proportion of participants achieving a reduction of at least 100 points from baseline in the IBS Symptom Severity Score (IBS-SSS) after 6 weeks of treatment.

    Time frame: Baseline and Week 6

  2. Proportion of participants achieving a ≥50% reduction in IBS Symptom Severity Score (IBS-SSS)

    Proportion of participants achieving a reduction of at least 50% from baseline in the IBS Symptom Severity Score (IBS-SSS) after 6 weeks of treatment.

    Time frame: Baseline and Week 6

  3. Change from baseline in IBS Symptom Severity Score (IBS-SSS)

    Absolute and percentage change from baseline in the IBS Symptom Severity Score (IBS-SSS). Scores range from 0 to 500, with higher scores indicating greater symptom severity.

    Time frame: Baseline, Week 3, and Week 6

  4. Change from baseline in gastrointestinal symptom severity (Visual Analog Scale)

    Absolute and percentage change from baseline in gastrointestinal symptom severity assessed using a Visual Analog Scale (VAS), with higher scores indicating greater symptom severity.

    Time frame: Baseline, Week 3, and Week 6

  5. Change in quality of life

    Change from baseline in IBS-specific quality of life measured using the IBS-Quality of Life questionnaire (IBS-QOL). Scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Baseline, Week 3, and Week 6

  6. Change in psychological distress

    Change from baseline in psychological distress assessed using the Hospital Anxiety and Depression Scale (HADS), a validated 14-item questionnaire consisting of two 7-item subscales assessing anxiety (HADS-A) and depression (HADS-D). Each subscale ranges from 0 to 21, with higher scores indicating greater symptom severity. Total HADS score ranges from 0 to 42, with higher scores indicating greater overall psychological distress.

    Time frame: Baseline, Week 3, and Week 6

  7. Change in extraintestinal symptoms

    Change from baseline in extraintestinal symptom burden assessed using a modified version of the Patient Health Questionnaire (PHQ-15), including 12 non-gastrointestinal items after exclusion of the three gastrointestinal symptom items (abdominal pain, constipation/diarrhea, and nausea/gas/indigestion). Each item is scored from 0 to 2, with higher scores indicating greater extraintestinal symptom burden.

    Time frame: Baseline, Week 3, and Week 6

  8. Change in intestinal permeability measured by fecal α1-antitrypsin (A1AT)

    Change from baseline in fecal α1-antitrypsin concentration, a biomarker of intestinal permeability.

    Time frame: Baseline, Week 3, and Week 6

  9. Change in fecal calprotectin concentration

    Change from baseline in fecal calprotectin concentration as a marker of intestinal inflammation.

    Time frame: Baseline, Week 3, and Week 6

  10. Change in gut microbiota composition

    Change from baseline in gut microbiota composition and diversity assessed by 16S rRNA gene sequencing.

    Time frame: Baseline, Week 3, and Week 6

  11. Participants' experiences with the dietary intervention

    Participants' perceptions, barriers, facilitators, and overall experiences with the assigned dietary intervention assessed through structured qualitative interviews.

    Time frame: Follow up: after completion of the 6-week intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 24 months is above that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2026
First posted
Jul 16, 2026
StartActual
Jul 19, 2026
Primary completionEst.
Jul 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added — first site in Israel
Show site
  • Sheba Medical Center, Tel Hashomer · Ramat Gan, Israel
Nov 10, 2026
Start date
Jul 7, 2026→Jul 19, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Israel
    Show site
    • Sheba Medical Center, Tel Hashomer · Ramat Gan, Israel
    Start date Jul 7, 2026→Jul 19, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07707635
Lead sponsor
Ariel University
Collaborators
Sheba Medical Center, Ministry of Innovation, Science and Technology of Israel
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 19, 2026
Primary completion
Jul 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Keren Hod, RD PhD
Contact
kerenho@ariel.ac.il
+972-53-2214380
Tal Engel, MD
Contact
talengel@gmail.com
+972-52-5752211
Keren Hod, RD PhD
study chair · Ariel University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion